Phase 4 N=17 Dichotic Listening as a Predictor of Medication Response in Depression
Major Depressive Disorder · Dysthymia
Primary: Hamilton Depression Scale (HAM-D) — 11.2; 9.7; 11.3 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,028 Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Prostate Cancer · Castration Resistant Prostate Cancer · Pain
Primary: Overall Survival (OS) — 11.0; 9.8 months — p=0.213
Phase 3 N=239 Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 96.2; 95.4; 96.0 percentage of participants
Phase 2 N=91 Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Gastrointestinal Stromal Tumor (GIST)
Primary: Recurrence-free Survival up to 60 Months — 9; 7; 2; 82 participants with an event
Phase 2 N=7 PF-06372865 in Subjects With Photosensitive Epilepsy
Reflex Epilepsy, Photosensitive
Primary: The Standardized Photosensitivity Range (SPR) in the Subject's Most Sensitive Eye Condition — 0.57; 1.38; 1.58; 6.80 Units on a scale
Phase 2 N=124 A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Index (EASI 50) — 37; 57; 61 percentage of participants — p==0.065
Phase 3 N=344 Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
Esophageal Cancer
Primary: Overall Survival (24-month Rate Reported) — 44.9; 44.0 percentage of participants — p=0.47
Phase 3 N=77 Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
Type 2 Diabetes Mellitus
Primary: Percentage of Participants Who Experienced at Least 1 Adverse Event (AE) — 77.9 Percentage of participants
Phase 4 N=100 RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Operative Vaginal Reconstruction Pain
Post Operative Pain
Primary: Pain While Active - 18 hr — 42.0; 50.0 mm — p=0.328
Phase 2 N=33 RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder
Bladder Cancer
Primary: Phase I - Dose-limiting Toxicity (DLT) — 0 DLT
Phase 3 N=352 Study Of Adults And Adolescents With Vasomotor Rhinitis
Rhinitis, Vasomotor
Primary: Mean Change From Baseline Over the Entire Treatment Period in Daily Reflective Total Nasal Symptom Score (rTNSS) — -1.71; -2.05 Score on scale — p=0.050
Phase 3 N=50 A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus
Respiratory Syncytial Virus (RSV)
Primary: Percentage of Participants With RSV Hospitalization — 0.0 percentage of participants
N/A N=128 Phone-Based Postpartum Continuing Care for Smoking Cessation
Smoking Cessation · Pregnancy
Primary: Number of Tobacco Products Per Day — 6.4; 6.9 tobacco products
Phase 3 N=198 Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
Moderate to Severe Nail Psoriasis
Primary: Percentage Change From Baseline in Nail Psoriasis Severity Index (NAPSI) After 16 Weeks of Treatment — -38.4; -46.1; -11.7 percent change — p=<0.0001
Phase 2 N=375 A New Oral Treatment For Type II Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 — 0.46; 0.18; -0.07; 0.01 Percentage of HbA1c — p=0.061